Abstract:Abstract Non-human primates (NHPs) represent the most valuable animals for drug discovery. However, the current main challenge remains that the NHP has not yet been used to develop an efficient translational medicine platform simulating human diseases, such as cancer. This study generated an in situ gene-editing approach to induce efficient loss-of-function mutations of Pten and p53 genes for rapid modeling primary and metastatic liver tumors using the CRISPR/Cas9 in the adult cynomolgus monkey. Under ultrasound guidance, the CRISPR/Cas9 was injected into the cynomolgus monkey liver through the intrahepatic portal vein. The results showed that the ultrasound-guided CRISPR/Cas9 resulted in indels of the Pten and p53 genes in seven out of eight monkeys. The best mutation efficiencies for Pten and p53 were up to 74.71% and 74.68%, respectively. Furthermore, the morbidity of primary and extensively metastatic (lung, spleen, lymph nodes) hepatoma in CRISPR-treated monkeys was 87.5%. The ultrasound-guided CRISPR system could have great potential to successfully pursue the desired target genes, thereby reducing possible side effects associated with hitting non-specific off-target genes, and significantly increasing more efficiency as well as higher specificity of in situ gene editing in vivo, which holds promise as a powerful, yet feasible tool, to edit disease genes to build corresponding human disease models in adult NHPs and to greatly accelerate the discovery of new drugs and save economic costs.

TALEN-mediated Gene Mutations in Monkeys

Generation of a Monkey with MECP2 Mutations by TALEN-based Gene Targeting.

TALEN-mediated gene mutagenesis in rhesus and cynomolgus monkeys.

[Applications of ZFN, TALEN and CRISPR/Cas9 Techniques in Disease Modeling and Gene Therapy].

Trio deep-sequencing does not reveal unexpected mutations in Cas9-edited monkeys

Various applications of TALEN- and CRISPR/Cas9-mediated homologous recombination to modify the Drosophila genome.

High-Efficiency And Heritable Gene Targeting In Mouse By Transcription Activator-Like Effector Nucleases

Trio Deep-Sequencing Does Not Reveal Unexpected Off-Target and On-Target Mutations in Cas9-edited Rhesus Monkeys

Utilization of TALEN and CRISPR/Cas9 technologies for gene targeting and modification.

Utilization of TALEN and CRISPR/Cas9 Technologies for Gene Targeting and Modification

Efficient Targeted Gene Disruption in Xenopus Embryos Using Engineered Transcription Activator-Like Effector Nucleases (Talens).

Gene targeting in the mouse: advances in introduction of transgenes into the genome by homologous recombination

Targeted Genome Editing in Primate Embryos

Generation of Gene-Modified Cynomolgus Monkey via Cas9/RNA-Mediated Gene Targeting in One-Cell Embryos

Generation of in situ CRISPR-mediated primary and metastatic cancer from monkey liver

Primer and interviews: advances in targeted gene modification. Interview by Julie C. Kiefer.

Precise Gene Modification Mediated by TALEN and Single-Stranded Oligodeoxynucleotides in Human Cells.

Recent advances in targeted genome engineering in mammalian systems.

[TALE Nuclease Engineering and Targeted Genome Modification].

Applications of Genome Editing Technology in the Targeted Therapy of Human Diseases:Mechanisms,advances and Prospects

Targeted Mutagenesis Of Arabidopsis Thaliana Using Engineered Tal Effector Nucleases